product name Vecuronium Bromide
Description: Vecuronium is a non-depolarizing neuromuscular blocking agent, used for skeletal muscle relaxation during surgery. Vecuronium inhibits both forms of the muscle-type acetylcholine receptor with IC50 of 1-2 mM. Vecuronium combined with methylprednisolone shows additive effects on both receptor forms, which is best described by a two-site model, with each site independent. Vecuronium interferes with nicotinic processes in the carotid body and inhibits the chemoreceptor neural response to hypoxia. Vecuronium significantly attenuates the increase in CSNA (DeltaCSNA) in response to hypoxia in the carotid body.
References: Anesthesiology. 2000 Mar;92(3):821-32; Anesth Analg. 2002 Jan;94(1):117-22; Anesth Analg. 1982 Apr;61(4):313-6.
637.73
Formula
C34H57N2O4.Br
CAS No.
50700-72-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (156.8 mM)
Water: 4 mg/mL (6.3 mM)
Ethanol: 100 mg/mL (156.8 mM)
Solubility (In vivo)
Synonyms
ORG NC45
other peoduct :
| In Vitro |
In vitro activity: Vecuronium inhibits both forms of the muscle-type acetylcholine receptor with IC50 of 1-2 mM. Vecuronium combined with methylprednisolone shows additive effects on both receptor forms, which is best described by a two-site model, with each site independent. Vecuronium interferes with nicotinic processes in the carotid body and inhibits the chemoreceptor neural response to hypoxia. Vecuronium significantly attenuates the increase in CSNA (DeltaCSNA) in response to hypoxia in the carotid body. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Vecuronium (a monoquaternary ammonium compound) has a higher biliary clearance than pancuronium (a bisquaternary ammonium compound) in the rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Anesthesiology. 2000 Mar;92(3):821-32; Anesth Analg. 2002 Jan;94(1):117-22; Anesth Analg. 1982 Apr;61(4):313-6. |
